Amarin in 'strong position' against Health Net, says Piper Sandler » 10:3501/2601/26/21
AMRN, GSK, TEVA
Amarin (AMRN) yesterday…
Amarin expands Vascepa patent infringement suit to include Health Net » 10:3201/2601/26/21
Amarin (AMRN) last night…
Humana unit partners in Primary Care announces growth plans » 09:2301/2601/26/21
Partners in Primary Care…
Teladoc price target raised to $330 from $260 at BTIG » 08:5101/2601/26/21
BTIG analyst David Larsen…
BTIG analyst David Larsen raised the firm's price target on Teladoc (TDOC) to $330 from $260 and keeps a Buy rating on the shares. The analyst notes that the stock's recent strength is driven by several factors, including the indication made by UnitedHealth (UNH) last week that it would work with multiple tele-health vendors, the recent spike in COVID cases driving the need for tele-health options, and the commentary by UnitedHealth about the durability of tele-health beyond the pandemic.
Allogene Therapeutics upgraded to Buy from Hold at Stifel » 06:0101/2601/26/21
Stifel analyst Benjamin…
Fly Intel: After-Hours Movers » 18:5301/2501/25/21
IPAR, GGG, FUL, WSFS, HXL, STLD, BDGE, STAA, IAC, NBTX, BCRX, JJSF, CR, KRMD, QUMU, SEEL, CVAC, ASO
Check out this evening's…
Sarissa Capital reports 5.0% passive stake in BioCryst » 16:4601/2501/25/21
Sarissa Capital disclosed…
Sarissa Capital disclosed a 5.0% stake in BioCryst, which represents over 8.84M shares. The filing does not allow for activism.
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated' » 16:0301/2501/25/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Louise Chen noted that the EU's CHMP published its agenda for meetings taking place this week, which includes reference to icosapent ethyl. The meeting timing puts Amarin in-line to "on the earlier side" of potentially receiving a CHMP opinion that it has said would occur in late January to early February of this year, according to Chen, who expects a positive CHMP opinion and for EMA approval to follow within 67 days of a CHMP decision. Chen, who thinks recent updates highlight the "underappreciated opportunities" for Vascepa outside of the U.S., keeps an Overweight rating on Amarin shares with a $10 price target.
Piper Sandler reiterates 'conviction call' on Amarin into European decision » 08:4601/2501/25/21
Piper Sandler analyst…
Piper Sandler analyst Yasmeen Rahimi reiterates reiterate her "conviction call" on Amarin's potential for European approval of Vascepa, with the Committee for Medicinal Products for Human Use opinion expected in late January or February. Potential European Medicines Agency approval 67 days after the CHMP recommendation is the most important stock-moving catalyst for Amarin shares in 2021, Rahimi tells investors in a research note. She continues to believe Amarin will have a "re-birth" in 202 on Vascepa's continued revenue growth and global market opportunity. The analyst keeps an Overweight rating on the shares with a $19 price target.
Humana names Nwando Olayiwola, M.D., Chief Health Equity Officer » 08:3801/2501/25/21
Leading health and…
Leading health and well-being company Humana has named Nwando Olayiwola, M.D., MPH, FAAFP, to the position of Senior Vice President and Chief Health Equity Officer. In this newly created role, Dr. Olayiwola will report directly to Humana Chief Medical and Corporate Affairs Officer William Shrank, M.D., and will set direction and establish strategy to promote health equity across all Humana lines of business, including its care delivery assets. She will lead work to define enterprise-wide measures of equity, create goals for improvement and coordinate efforts to achieve them. In addition, Dr. Olayiwola will further Humana's focus on cultural sensitivity, ensuring that it's fully integrated into the design and development of Humana clinical programs, products, services and all member interactions and communications, while working collaboratively with the broader health care community to advance health equity so health care can work better for everyone, regardless of background, age or economic status. Dr. Olayiwola will assume the role effective April 5, 2021.